COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,704 Articles (22,913 medRxiv, 8,791 bioRxiv)

Most recent first Previous |  Page 730: Articles 7291-7300  | Next

Failure to balance social contact matrices can bias models of infectious disease transmission
Hamilton, M. A., Knight, J., Mishra, S.
10.1101/2022.07.28.22278155 — Posted: 2022-07-31
The Effect of the COVID-19 Pandemic on Mental Health in Low and Middle Income Countries
Aksunger, N., Vernot, C., Littman, R., Voors, M., Meriggi, N., Abajobir, A., Beber, B., Dai, K., Egger, D., Islam, A., Kelly, J., Kharel, A., Matabaro, A., Moya, A., Mwachofi, P., Nekesa, C., Ochieng, E., Rahman, T., Scacco, A., Van Dalen, Y., Walker, M., Janssens, W., Mobarak, A. M.
10.1101/2022.07.29.22278182 — Posted: 2022-07-31
Has the pandemic enhanced and sustained digital health-seeking behaviour? A big-data interrupted time-series analysis of Google Trends
van Kessel, R., Kyriopoulos, I., Wong, B. L. H., Mossialos, E.
10.1101/2022.07.29.22278191 — Posted: 2022-07-30
Comparative effectiveness of BNT162b2 versus mRNA-1273 boosting in England: a cohort study in OpenSAFELY-TPP
Hulme, W. J., Horne, E. M. F., Parker, E. P. K., Keogh, R. H., Williamson, E. J., Walker, V., Palmer, T., Curtis, H. J., Walker, A., Mehrkar, A., Morley, J., MacKenna, B., Bacon, S. C. J., Goldacre, B., Hernan, M. A., Sterne, J. A. C.
10.1101/2022.07.29.22278186 — Posted: 2022-07-30
Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland
Zaballa, M.-E., Perez-Saez, J., de Mestral, C., Pullen, N., Lamour, J., Turelli, P., Raclot, C., Baysson, H., Pennacchio, F., Villers, J., Duc, J., Richard, V., Dumont, R., Semaani, C., Loizeau, A. J., Graindorge, C., Lorthe, E., Balavoine, J.-F., Pittet, D., Schibler, M., Vuilleumier, N., Chappuis, F., Kherad, O., Azman, A. S., Posfay-Barbe, K., Kaiser, L., Trono, D., Stringhini, S., Guessous, I., Specchio-COVID19 study group
10.1101/2022.07.27.22278126 — Posted: 2022-07-29
OM-85 reduces SARS-COV-2 viral RNA expression in nasopharyngeal cells from COVID-19 patients
Cassao, G., Antunes, K. H., Goncalves, J. I. B., Santos, L. D., Abbadi, B. L., Bizarro, C. V., Machado, P., Basso, L. A., Pasquali, C., Stein, R., Souza, A. P. D. d.
10.1101/2022.07.29.502045 — Posted: 2022-07-29
Infection- or vaccine mediated immunity reduces SARS-CoV-2 transmission, but increases competitiveness of Omicron in hamsters
Port, J. R., Yinda, C. K., Riopelle, J. C., Weishampel, Z. A., Saturday, T. A., Avanzato, V. A., Schukz, J. E., Holbrook, M. G., Barbian, K., Perry-Gottschalk, R., Haddock, E., Martens, C., Shaia, C. I., Lambe, T., Gilbert, S. C., van Doremalen, N., Munster, V. J.
10.1101/2022.07.29.502072 — Posted: 2022-07-29
An agent-based modelling framework for assessing SARS-CoV-2 indoor airborne transmission risk
Knapp, S. O., Dunne, R., Tabor, B., Hickson, R. I., Dunstall, S.
10.1101/2022.07.28.22278138 — Posted: 2022-07-29
Risk factors among Black and White COVID-19 patients from a Louisiana Hospital System, March, 2020-August, 2021
Yu, Q., Cao, W., Hamer, D., Urbanek, N., Straif-Bourgeois, S., Cormier, S., Ferguson, T., Richmond-Bryant, J.
10.1101/2022.07.27.22278118 — Posted: 2022-07-29
SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection.
Ward, K. E., Steadman, L., Karim, A. R., Reynolds, G. M., Pugh, M., Faustini, S. E., Veenith, T., Thwaites, R. S., Openshaw, P. J., Drayson, M. T., Shields, A. M., Cunningham, A. F., Wraith, D. C., Richter, A. G.
10.1101/2022.07.26.22278002 — Posted: 2022-07-29

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).